2010/SOM3/LSIF/002. Opening Remarks. Submitted by: Japan Pharmaceutical Manufacturers Association (JPMA)

Transcription

1 010/SOM/LSIF/00 Opening Remarks Submitted by: Japan Pharmaceutical Manufacturers Association (JPMA) Life Sciences Innovation Forum Sendai, Japan September 010

2 Message From JPMA President APEC Life Sciences Innovation Forum September 18, 010, Sendai, Japan Mr. Yasuchika Hasegawa Opening Messages from JPMA President, Mr. Hasegawa in APEC LSIF NB: Life Sciences Innovation Forum - Asia-Pacific Economic Cooperation Good morning, ladies and gentlemen. I am Yasuchika Hasegawa, President of Japanese Pharmaceutical Manufacturers Association, which we affectionately refer to as the JPMA. As some of you may know, I am also President & CEO of Takeda Pharmaceutical Company Limited. Firstly, I would like to apologize for not attending in person due to a pressing prior commitment; however please allow me to say that it is truly an honor to have this opportunity to speak with you via video following welcome remarks by Mr. Hidehiko Nishiyama, Director-General, Trade Policy Bureau, Ministry of Economy, Trade and Industry of Japan, and two remarks by His Excellency Minister Suwit, Chair of LSIF, Minister of Natural Resources and the Environment, Thailand, and Ms. Barbara Norton, Chair of the LSIF Planning Group, Office of the U.S. Trade Representative, United States. (Basic recognition of Life-science) Given the importance of this meeting, I would like to share with you my perspectives about life science innovation. The 0 th century was an the century of science while the 1 st century will be the century of life. The driver of this change was the rapid progress made in bio-technology and the understanding of life phenomena that this technology allows. However, I don t think this is the only reason why this century is being called the century of life. We all of us in the world are now facing a number of challenging issues, and it is likely that the life-sciences will contribute to the solutions, such as, realizing a stable food supply in the midst of global climate change and an increasing population, the development of alternate energies to fossil fuels, and treatments for both new and reemerging pandemics such as both new and conventional types of influenza. 1 / 4

3 Drug contribution to treatment (Value of LSIF) One issue shared around the world today is the issue of the aging population. Some economies in the Asia-Pacific region have already aged considerable and it is certain that other economies will also follow in the not too distant future. This should be a key driver for all of us here to cooperate in managing health and medical issues. As you all know, the objectives of Life Sciences Innovation Forum--or LSIF is growth and socio-economic development as healthy people produce healthy economies. Taking this opportunity, I would like to acknowledge His Excellency, Minister Suwit s foresight and leadership in establishing LSIF. (Role of the Pharmaceutical Industry) Now, please allow me to talk about the role of pharmaceutical industry in the innovation of the life-sciences. Throughout its history, the pharmaceutical industry has always been quick to take in and use the most cutting-edge knowledge in life-sciences, which we then built on ourselves through further research. Likewise, today we are conducting research in cutting-edge areas such as the genome and protein research to translate these promising new technologies into the innovative medicines of tomorrow. Please see the slide. New Drug Development Status by Therapeutic Satisfaction in 005 (as of May 009) 100% Peptc ulcer 18 items (8.1%) 79 items (5.6%) 90% Concretion podagra 1 1 Hyperlipidemia Diabetes mellitus High blood 80% 1 pressure 6 Angina Asthma Allergic rhinitis Epileptic 0 70% Depression Cardiac failure 1 6 Cardiac infarction 5 Arrhythmia Neurosis anxiety 60% Chronic hepatitis B Hyperplasia of prostate Functional dyspepsia 1 Parkinson s Rheumatoid Chronic hepatitis C 9 Glaucoma disease arthritis 50% 6 1 Leucemia Inflammatory bowl disease MRSA 40% Nephrosis Brain infarct 8 Adenocarcinoma of prostate Integration disorder syndrome IBS 1 Endometriosis SLE 9 COPD 6 Atopic dermatitis Breast cancer Cerebral Osteoporosis 8 0% Diabetic renal disease AIDS haemorrhage 1 Overactive bladder Psoriatic Cirrhosis liver Stress urinary Chronic glomerulonephritis 6 7 Cancer of stomach 0% Disseminierte incontinence Decubitus Herdsklerose Large intestine Arthropathie 1 Fibroid of the uterus Chronic deformans carcinoma renal failure Diabetic 4 1 Cancer of uterus neuropahy Lung 10 5 Hepatic cancer 1 Sleep apnea cancer 10% Age-related macular 7 degeneration Diabetic retinopathy Alzheimer's Vascular dementia disease 94 items (4.%) 1 items (14.0%) 0% 0% 10% 0% 0% 40% 50% 60% 70% 80% 90% 100% Data by the Office of Pharmaceutical Industry Research (compiled in May 009) Satisfaction with treatment Note: Covered in the above chart are drugs developed by the 0 most selling Japanese drug makers in 008 (Astellas, AstraZeneca, Abbott, Eisai, Otsuka, Ono, Kyowa Hakko Kirin, GlaxoSmithKline, Sanofi-Aventis, Shionogi, Daiichi Sankyo, Dainippon Sumitomo, Takeda, Mitsubishi Tanabe, Chugai, Nippon Boehringer, Novartis, Bayer, Banyu and Pfizer). Covered products are either drugs including new active ingredients, or drugs with new indications, from Phase I to approval pending, based on the information published on the manufacturer websites, or the information registered with the JPMA s Drugs under Development website, as of May 009. This scope included 77 new developments, of which total items (178 drugs) pertained to the 60 diseases targeted by the therapeutic satisfaction survey in FY005. / 4

4 This slide shows therapeutic areas where the JPMA member companies have developed medicines. As you can see, the vertical axis indicates the level of contribution of the medicines to treatment, while the horizontal measure indicates the level of overall satisfaction in treatment which is not limited to just drug therapy. What can be recognized from this slide is that many pharmaceutical companies are in fact working on diseases in the lower left corner which consists of unmet medical needs. Our industry has been contributing to the safe and full lives of people around the world by providing innovative and effective new medicines to patients for a variety of diseases. (Challenges facing life-innovation) However, there are significant new challenges in the development of new medicines. As more progress is made, we find more and more complex and diversified factors being expressed within life processes, which make it very challenging for an individual pharmaceutical company to invent innovative medicines alone. Currently, pharmaceutical companies are investing huge amounts of money into internal research and development activities, but in addition to that, I think a broad range of alliances with venture companies and academia, and also a commitment for support from the government to promote such alliance are the key factors to achieve innovation into the future. In June this year, the Japanese government announced its New Growth Strategy, and we are encouraged with the fact that Life Innovation is defined as the strategic areas as well as Environment. From now on, together with the enhanced incentives for venture companies, it is planned to improve the infrastructure for clinical development, and also for speedier review of New Drug Applications. / 4

5 (Cooperation with Asia) In this New Growth Strategy, it is clearly stated that Japan would like to play the role of being a bridge across Asia, with Japan acting as a growth engine by sharing its experience. Likewise, when I assumed the Presidency of the JPMA this May, I made a proposal to enhance cooperation with the pharmaceutical industry associations in Asian economies through vitalized communication at the industry level, as well as to enhance dialogue with the government on drug discovery issues. To date, the JPMA has contributed to Asian economies through activities, such as capacity building of expertise in the industry, supply of materials for quality assurance, cooperation in the eradication of counterfeit medicines. All of these activities are consistent with the objectives of the LSIF. I believe that there are several important areas where JPMA and LSIF can collaborate, such as harmonization of Good Manufacturing Practices regulations, the development and harmonization of intellectual property rights, which will promote innovation, and also the nurture of experts in both areas. With participants representing the governments, academia and industry throughout the APEC economies, this forum is an invaluable opportunity to share ideas on the issues before us in life innovation. I look forward to hearing more on the fruitful discussions that you will all be having. Thank you very much for your attention. 4 / 4